![conference banner](/images/conference-banner.jpeg)
Abstract
Selegiline inhibits the activity of monoamine oxidase B, enhances the release of dopamine, blocks the uptake of dopamine, acts as a calmodulin antagonist, and enhances the level of cyclic AMP, which in turn protects dopaminergic neurons. It possesses cognition- enhancing functions, rejuvenates serum insulin-like growth factor I in aged rats, and enhances life expectancy in rodents. Selegiline possesses neurotrophic-like actions, and rescues axotomized motorneurons independent of monoamine oxidase B inhibition. It enhances the synthesis of nerve growth factor, protects dopaminergic neurons from glutamate-mediated neurotoxicity, and protects dopaminergic neurons from toxic factors present in the spinal fluid of parkinsonian patients, and the said effect may be mediated via elaborating brain derived neurotrophic factor. Selegiline increases the striatal superoxide dismutase, protects against peroxynitrite- and nitric oxide-induced apoptosis, and guards dopaminergic neurons from toxicity induced by glutathione depletion. It stimulates the biosynthesis of interleukin 1-β and interleukin-6, is an immunoenhancing substance, possesses antiapoptotic actions, and is neuroprotectant in nature. Selegiline has been shown to be efficacious in Parkinsons disease, global ischemia, Gille de la Tourette syndrome, and narcolepsy. Its therapeutic efficacy in Alzheimers disease remains uncertain. In Alzheimers disease, short term studies of selegiline suggest a beneficial effect; whereas long term studies are less convincing.
Keywords: MPTP, 6-hydroxydopamine, Selegiline, Rasagiline, Monoamine Oxidase B, Parkinson's Disease, Alzheimer's Disease, Neurorestoration, Neuroprotection
Current Drug Targets
Title: Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Volume: 7 Issue: 11
Author(s): Manuchair Ebadi, Holly Brown-Borg, Jun Ren, Sushil Sharma, Shaik Shavali, Hesham El ReFaey and Edward C. Carlson
Affiliation:
Keywords: MPTP, 6-hydroxydopamine, Selegiline, Rasagiline, Monoamine Oxidase B, Parkinson's Disease, Alzheimer's Disease, Neurorestoration, Neuroprotection
Abstract: Selegiline inhibits the activity of monoamine oxidase B, enhances the release of dopamine, blocks the uptake of dopamine, acts as a calmodulin antagonist, and enhances the level of cyclic AMP, which in turn protects dopaminergic neurons. It possesses cognition- enhancing functions, rejuvenates serum insulin-like growth factor I in aged rats, and enhances life expectancy in rodents. Selegiline possesses neurotrophic-like actions, and rescues axotomized motorneurons independent of monoamine oxidase B inhibition. It enhances the synthesis of nerve growth factor, protects dopaminergic neurons from glutamate-mediated neurotoxicity, and protects dopaminergic neurons from toxic factors present in the spinal fluid of parkinsonian patients, and the said effect may be mediated via elaborating brain derived neurotrophic factor. Selegiline increases the striatal superoxide dismutase, protects against peroxynitrite- and nitric oxide-induced apoptosis, and guards dopaminergic neurons from toxicity induced by glutathione depletion. It stimulates the biosynthesis of interleukin 1-β and interleukin-6, is an immunoenhancing substance, possesses antiapoptotic actions, and is neuroprotectant in nature. Selegiline has been shown to be efficacious in Parkinsons disease, global ischemia, Gille de la Tourette syndrome, and narcolepsy. Its therapeutic efficacy in Alzheimers disease remains uncertain. In Alzheimers disease, short term studies of selegiline suggest a beneficial effect; whereas long term studies are less convincing.
Export Options
About this article
Cite this article as:
Ebadi Manuchair, Brown-Borg Holly, Ren Jun, Sharma Sushil, Shavali Shaik, El ReFaey Hesham and Carlson C. Edward, Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases, Current Drug Targets 2006; 7 (11) . https://dx.doi.org/10.2174/1389450110607011513
DOI https://dx.doi.org/10.2174/1389450110607011513 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research In Vitro Effects of Arylhydrocoumarin on Free Radicals and Oxidative Stress in Erythrocytes and Saccharomyces cerevisiae
Current Pharmaceutical Biotechnology New Approaches for the Treatment of Pain: The GDNF Family of Neurotrophic Growth Factors
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research Meet Our Editorial Board Member
Recent Patents on Anti-Infective Drug Discovery Secondary Degeneration of White Matter Tract following Basal Ganglia Infarction: A Longitudinal Diffusion Tensor Imaging Study
Current Medical Imaging The Seek of Neuroprotection: Introducing Cannabinoids
Recent Patents on CNS Drug Discovery (Discontinued) Activity-Dependent Synapse Modulation and the Pathogenesis of Alzheimer Disease
Current Alzheimer Research Natural Medicinal Compounds Used in Neurodegenerative Diseases
Current Functional Foods Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine The Catalytic Activity of TiO<sub>2</sub> Toward a Multicomponent Reaction Depends on its Morphology, Mechanoactivation and Presence of Visible Light
Journal of Photocatalysis The Neuroprotective Properties of Thymol and Carvacrol: A Review Study
The Natural Products Journal Acridine: A Scaffold for the Development of Drugs for Alzheimer's Disease
Current Topics in Medicinal Chemistry Oral Supplements of <i>Ginkgo biloba</i> Extract Alleviate Neuroinflammation, Oxidative Impairments and Neurotoxicity in Rotenone-Induced Parkinsonian Rats
Current Pharmaceutical Biotechnology Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Hydrogen-producing Photocatalyst at Sunscreen for Athletes in Preventing and Healing Muscle-nerve-skin Injuries
Current Topics in Medicinal Chemistry Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties
Current Alzheimer Research The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease
Current Alzheimer Research MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research